, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, supported by Takeda, we had the pleasure of speaking with Onyee Chan, MD, a hematologist/oncologist at the Moffitt Cancer Center Magnolia Campus in Tampa, Florida, and Bradley D. Hunter, MD, the medical director of Oncology and the director of Immune Effector Cell Therapy at Intermountain Healthcare in Salt Lake City, Utah, about evolving treatment strategies in chronic myeloid leukemia (CML).

In our exclusive interview, Drs Chan and Hunter discussed the integration of asciminib (Scemblix) as a first-line therapy for patients with CML, optimal treatment sequencing in CML management, and how findings from the phase 2 OPTIC trial (NCT02467270) have influenced ponatinib (Iclusig) dosing strategies in patients with chronic-phase disease. They also addressed the role of mutational testing in guiding treatment selection, strategies to mitigate adverse effects, and the evolving role of stem cell transplantation in the treatment paradigm.

That’s all we have for today! Thank you for listening to this episode of 

, supported by Takeda. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

 is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Podcasts

Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.

Bradley D. Hunter, MD

Articles

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD